Brainomix’s AI-based quantitative lung imaging technology has been used to successfully detect therapeutic benefit in a clinical trial evaluating an experimental drug for a type of lung disease.
The use of Brainomix 360 e-Lung, an AI-powered image analysis tool, was evaluated in a post-hoc analysis of Endeavor BioMedicine’s Phase IIa trial evaluating its hedgehog pathway inhibitor, taladegib, in patients with idiopathic pulmonary fibrosis (IPF), with findings shared at the 2026 European Respiratory Society (ERS) congress, taking place 5-9 September in Barcelona, Spain.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In a post-hoc analysis of Endeavor’s 12-week Phase IIa ENV-IPF-101 trial, through the use of e-Lung’s quantitative CT imaging provision, “significant positive differences” in favour of taladegib in lung volume, overall ILD burden and total fibrosis extent were observed.
These findings highlight the potential of AI-powered quantitative imaging outputs to support the detection of meaningful treatment effects in small, relatively short clinical studies, supporting more efficient and informed clinical development, the companies stated. The findings also indicate the efficacy of Endeavour’s candidate in treating IPF.
Dr Lisa Lancaster, CMO at Endeavor BioMedicines, commented: “The results of Brainomix’s post hoc quantitative imaging analysis continue to support taladegib’s potential to improve lung structure, reduce fibrosis and improve lung function in patients with IPF.
“We are impressed with the technology’s ability to detect statistically significant changes in a small cohort and over a short treatment duration. These results are a testament to the value of objective, sensitive and reliable endpoints for the de-risking of clinical development, and we look forward to future collaboration opportunities with Brainomix.”
Brainomix and Endeavor originally entered into their collaboration to conduct a post-hoc analysis evaluating the potential of Brainomix AI-powered quantitative imaging outputs to support clinical trials. Trained on diverse datasets, the platform has been employed in several Phase II and Phase III trials and became the first quantitative CT imaging platform selected as a co-primary endpoint in a Phase IIIb pulmonary fibrosis trial.
Commenting on the findings presented at ERS, professor Peter George, consultant pulmonologist at the Royal Brompton Hospital, UK, and senior medical director at Brainomix, said: “Our goal is to accelerate the clinical development of potentially transformational treatments, and taladegib is one of the most promising therapies for pulmonary fibrosis currently in development.
“We are very pleased to see that our analysis with e-Lung was able to provide key insights into the efficacy and mechanism of taladegib.”
